Another interesting observation in the analysis was the following statement;
In order to advance its pipline through different clinical stages and commercialisation, the Company has signed a clinical trial supply agreement with pharmaceutical giants Roche (SWX: ROG) and Merke KGaA (ETR: MRK), adding further validation to its pipeline candidates.The company’s pipeline indication represents a Multi-Million-Dollar market opportunity targeting the highly valuable market of cancer immunotherapy.
Could anyone familiar with these type of agreements enlighten the wider community on what this means exactly?
DYOR opinion only
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)